Cell Metabolism, launched in January 2005, is one of the newer titles in the Cell Press family. The journal focuses on physiology, with an emphasis on understanding the molecular basis of how the ...

Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

The network is called Lunar Surface Communication System (LSCS), and it is basically a replica of the 4G/LTE cellular technology currently used on a very large scale by the humans of Earth.

Two new “pioneering” open-access scale-up facilities focused on advancing cellular agriculture are at the centre of a €12.5m investment grant from the Dutch National Growth Fund for Cellular ...

It looks like T-Mobile is now accepting customers into the free beta program for SpaceX’s cellular Starlink service—but only if you have the latest Samsung handsets. On Tuesday, a number of T ...

In his book The Mathematical Universe, mathematician William Dunham wrote of John Venn’s namesake legacy, the Venn diagram, “No one in the long history of mathematics ever became better known ...

Both companies are committing to transforming and scaling AI skilling and learning for learners, workers and employers Pearson to further benefit from Microsoft Azure Cloud capabilities and AI tools, ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said. A ...